article thumbnail

Venus Remedies gains Malaysian PIC/S GMP approval for pre-filled syringe facility

Express Pharma

The global enoxaparin market was valued at US $3,315 million in 2023 and is projected to reach US $5,415 million by 2030, growing at a rate of 7.1 per cent from 2024 to 2030. PIC/S comprises 52 active member states and fosters cooperation between regulatory authorities and the pharmaceutical industry to promote GMP.

article thumbnail

QMS market to value nearly $4b by 2030

European Pharmaceutical Review

A market report by Meticulous Research has reported that rising pressure to reduce overall process costs has meant many pharma and biotech manufacturers are focusing on streamlining their processes by using quality management systems. According to the research, the pharmaceutical quality management systems market is projected to reach $3.97

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

17th edition of CPHI & PMEC India inaugurated at India Expo Centre, Noida

Express Pharma

The 17th edition of CPHI & PMEC India, organised by Informa Markets in India opened its doors at the India Expo Centre, Greater Noida, Delhi-NCR, showcasing the robust potential of India’s pharmaceutical industry. Projections indicate exports will soar to $130 billion by 2030 and $450 billion by 2047.

Packaging 105
article thumbnail

CPHI & PMEC India expo to be held from Nov 26-28, 2024

Express Pharma

Renowned as a comprehensive, one-stop destination for innovative, cost-effective solutions, the expo will be showcasing the pharmaceutical industry’s modernisation, innovation, and sustainability. India’s pharma industry is on an impressive growth trajectory, expected to reach $65 billion by 2024 and to double to $130 billion by 2030.

article thumbnail

Responsible sourcing and manufacturing: Growing towards a sustainable future with Lonza

Express Pharma

We have committed to reduce our scope 1 and 2 GHG emissions by 42 per cent (absolute) by the end of 2030 (from a 2021 basis). To achieve this goal, the company is focusing on transitioning to renewable electricity and carbon-free heat, reducing energy consumption, and redesigning manufacturing processes to reduce energy consumption and waste.

Dosage 104
article thumbnail

Innovative radioligand manufacturing facility inaugurated

European Pharmaceutical Review

The first industrial-scale pharmaceutical manufacturing facility for production of lead-212-based radioligand therapies has been inaugurated. The company hopes to produce this number tenfold by the end of 2030.

article thumbnail

Biopharma successful in achieving climate-related goals, report finds

European Pharmaceutical Review

According to the Intergovernmental Panel on Climate Change (IPCC), emissions must achieve reduction of 43 percent by 2030. Sustainable energy strategies for pharmaceutical manufacturers… The post Biopharma successful in achieving climate-related goals, report finds appeared first on European Pharmaceutical Review.